T Andersson

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi request reprint Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study
    June Zhao
    AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Clin Ther 28:1868-76. 2006
  2. ncbi request reprint Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers
    M Niazi
    AstraZeneca R and D, Molndal, Sweden
    Int J Clin Pharmacol Ther 47:564-9. 2009
  3. ncbi request reprint Effect of esomeprazole with/without acetylsalicylic Acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    Tommy Andersson
    AstraZeneca R and D, Pepparedsleden 1, 431 83, Molndal, Sweden
    Am J Cardiovasc Drugs 14:217-27. 2014
  4. doi request reprint Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers
    Tommy Andersson
    Clinical RD, AstraZeneca RD, Molndal, Sweden
    Am J Cardiovasc Drugs 12:217-24. 2012
  5. ncbi request reprint Stereoselective disposition of proton pump inhibitors
    Tommy Andersson
    Clinical Pharmacology and DMPK, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Drug Investig 28:263-79. 2008
  6. ncbi request reprint Single-isomer drugs: true therapeutic advances
    Tommy Andersson
    Experimental Medicine, AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Clin Pharmacokinet 43:279-85. 2004
  7. ncbi request reprint Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
    T Andersson
    Clinical Pharmacology, AstraZeneca LP, 725 Chesterbrook Blvd, Wayne, PA 19087 5677, USA
    Aliment Pharmacol Ther 15:1563-9. 2001
  8. ncbi request reprint Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
    M Hassan-Alin
    Experimental Medicine, AstraZeneca Research and Development Mölndal, Sweden
    Eur J Clin Pharmacol 56:665-70. 2000
  9. ncbi request reprint Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
    T Andersson
    Research Laboratories, AB Häsle, Molndal, Sweden
    Clin Pharmacol Ther 47:79-85. 1990
  10. ncbi request reprint A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects
    M Hassan-Alin
    Experimental Medicine, AstraZeneca R and D Molndal, 43183, Molndal, Sweden
    Eur J Clin Pharmacol 60:779-84. 2005

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study
    June Zhao
    AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Clin Ther 28:1868-76. 2006
    ....
  2. ncbi request reprint Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers
    M Niazi
    AstraZeneca R and D, Molndal, Sweden
    Int J Clin Pharmacol Ther 47:564-9. 2009
    ..To evaluate the effect of esomeprazole on the pharmacokinetics of low-dose acetylsalicylic acid (ASA) during repeated co-administration...
  3. ncbi request reprint Effect of esomeprazole with/without acetylsalicylic Acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    Tommy Andersson
    AstraZeneca R and D, Pepparedsleden 1, 431 83, Molndal, Sweden
    Am J Cardiovasc Drugs 14:217-27. 2014
    ..The effect of proton pump inhibitors (PPIs) on the pharmacokinetics and pharmacodynamics of clopidogrel was assessed in two healthy volunteer crossover studies...
  4. doi request reprint Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers
    Tommy Andersson
    Clinical RD, AstraZeneca RD, Molndal, Sweden
    Am J Cardiovasc Drugs 12:217-24. 2012
    ..The absence of a pharmacokinetic interaction between the proton pump inhibitor esomeprazole (40 mg) and acetylsalicylic acid (aspirin, ASA; 325 mg) has previously been established...
  5. ncbi request reprint Stereoselective disposition of proton pump inhibitors
    Tommy Andersson
    Clinical Pharmacology and DMPK, AstraZeneca R and D Molndal, Molndal, Sweden
    Clin Drug Investig 28:263-79. 2008
    ....
  6. ncbi request reprint Single-isomer drugs: true therapeutic advances
    Tommy Andersson
    Experimental Medicine, AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Clin Pharmacokinet 43:279-85. 2004
    ..Thus, from this example it is clear that the exploration and development of single-isomer drugs may bring significant advances in treatment options...
  7. ncbi request reprint Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
    T Andersson
    Clinical Pharmacology, AstraZeneca LP, 725 Chesterbrook Blvd, Wayne, PA 19087 5677, USA
    Aliment Pharmacol Ther 15:1563-9. 2001
    ..Esomeprazole, the S-isomer of omeprazole, is the first proton pump inhibitor developed as a single isomer for the treatment of acid-related diseases...
  8. ncbi request reprint Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
    M Hassan-Alin
    Experimental Medicine, AstraZeneca Research and Development Mölndal, Sweden
    Eur J Clin Pharmacol 56:665-70. 2000
    ..The main metabolites of esomeprazole were also assessed after the 40-mg oral dose...
  9. ncbi request reprint Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
    T Andersson
    Research Laboratories, AB Häsle, Molndal, Sweden
    Clin Pharmacol Ther 47:79-85. 1990
    ..The mean plasma concentrations of desmethyldiazepam showed a more rapid formation in the rapid compared with the slow metabolizers, which is a logical consequence of the rate of diazepam metabolism...
  10. ncbi request reprint A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects
    M Hassan-Alin
    Experimental Medicine, AstraZeneca R and D Molndal, 43183, Molndal, Sweden
    Eur J Clin Pharmacol 60:779-84. 2005
    ..To investigate the pharmacokinetics of S-omeprazole (esomeprazole), R-omeprazole and racemic omeprazole following single and repeated oral doses of 20 mg and 40 mg of each compound in healthy male and female subjects...
  11. ncbi request reprint Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects
    M Hassan-Alin
    Clinical Pharmacology, AstraZeneca Research and Development, Molndal, Sweden
    Int J Clin Pharmacol Ther 44:119-27. 2006
    ..A combination of esomeprazole, amoxicillin and clarithromycin may be used for Helicobacter pylori eradication. We explored the potential for interactions between these drugs...
  12. ncbi request reprint Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole
    T Andersson
    Clinical Pharmacology, AstraZeneca LP, Wayne, Pennsylvania 19087, USA
    Clin Pharmacokinet 40:523-37. 2001
    ..The increased plasma concentrations of esomeprazole are unlikely to have any safety implications. It can be concluded that the potential for drug-drug interactions with esomeprazole is low, and similar to that reported for omeprazole...
  13. ncbi request reprint Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing
    M B Sostek
    Clinical Research, Biostatistics and Experimental Medicine, AstraZeneca LP, Wilmington, DE 19850 5437, USA
    Aliment Pharmacol Ther 18:581-6. 2003
    ..To determine if nasogastric tube administration of the enteric-coated pellets from an opened esomeprazole capsule provides bioavailability similar to oral dosing with the intact capsule...
  14. ncbi request reprint Pharmacokinetic study of esomeprazole in the elderly
    G Hasselgren
    AstraZeneca R and D, Molndal, Sweden
    Clin Pharmacokinet 40:145-50. 2001
    ..The aim of this study was to examine the pharmacokinetics and tolerability of esomeprazole in the elderly, relative to middle-aged patients with gastro-oesophageal reflux disease (GORD)...
  15. ncbi request reprint Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
    T Andersson
    Clinical Pharmacology, AstraZeneca LP, Wayne, Pennsylvania, 19087, USA
    Clin Pharmacokinet 40:411-26. 2001
    ..A slight sex difference in the pharmacokinetics of esomeprazole was demonstrated in that the AUC and peak plasma drug concentration were slightly, but not statistically significantly, higher in females than in males...
  16. ncbi request reprint Effect of omeprazole and cimetidine on plasma diazepam levels
    T Andersson
    Research Laboratories, AB Hässle, Molndal, Sweden
    Eur J Clin Pharmacol 39:51-4. 1990
    ..However, since diazepam has a wide therapeutic range, it is unlikely that concomitant treatment with therapeutically recommended doses of either omeprazole or cimetidine will result in a clinically significant interaction with diazepam...
  17. ncbi request reprint Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers
    M Niazi
    AstraZeneca R and D, Molndal, Sweden
    Int J Clin Pharmacol Ther 49:169-76. 2011
    ..The aim of this study was to investigate the bioequivalence of a single oral dose of esomeprazole 40 mg and acetylsalicylic acid 325 mg when formulated as a single capsule, relative to the components given as separate monotherapies...
  18. ncbi request reprint Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion
    P Lindberg
    Gastrointestinal Therapy Area, AstraZeneca R and D, Molndal, Sweden
    Aliment Pharmacol Ther 17:481-8. 2003
    ..Esomeprazole therapy is well tolerated, with a low adverse events profile, similar to that seen with omeprazole...
  19. ncbi request reprint Omeprazole disposition in children following single-dose administration
    Gregory L Kearns
    Departments of Pediatrics and Pharmacology, University of Missouri, Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children s Mercy Hospitals and Clinics, Kansas City, Missouri, USA
    J Clin Pharmacol 43:840-8. 2003
    ..No association between age and CL/F, t1/2, or lambda z was observed. The range of t1/2 values for omeprazole was similar to those reported in adults (1-1.5 h)...
  20. ncbi request reprint Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease
    Staffan Edsbacker
    AstraZeneca R and D Lund, S 227 87 Lund, Sweden
    Clin Pharmacokinet 43:803-21. 2004
    ....
  21. ncbi request reprint Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study
    Jianguo Li
    AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
    Clin Ther 28:419-27. 2006
    ..The aim of this study was to assess the pharmacokinetic (PK) properties and tolerability of esomeprazole 20 and 40 mg after single and repeated oral doses in adolescents with symptoms of gastroesophageal reflux disease (GERD)...
  22. pmc Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole
    Mark B Sostek
    AstraZeneca LP, Wilmington, DE, USA
    Br J Clin Pharmacol 64:386-90. 2007
    ..To investigate the pharmacokinetics of esomeprazole before a high-fat meal vs. fasting...
  23. ncbi request reprint p38 Mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis
    Maria Alvarado-Kristensson
    Experimental Pathology, Department of Laboratory Medicine, Lund University, U MAS, S 205 02 Malmo, Sweden
    FASEB J 16:129-31. 2002
    ....
  24. ncbi request reprint p38 MAPK mediates TNF-induced apoptosis in endothelial cells via phosphorylation and downregulation of Bcl-x(L)
    Simone Grethe
    Division of Experimental Pathology, Department of Laboratory Medicine, University Hospital MAS, Lund University, Malmo, Sweden
    Exp Cell Res 298:632-42. 2004
    ..Taken together, our results suggest that TNF-induced p38 MAPK-mediated phosphorylation of Bcl-x(L) in endothelial cells leads to degradation of Bcl-x(L) in proteasomes and subsequent induction of apoptosis...
  25. ncbi request reprint The adhesion receptor CD-31 can be primed to rapidly adjust the neutrophil cytoskeleton
    Ivan Dimitrijevic
    Experimental Pathology, Department of Laboratory Medicine, Lund University, U MAS, Malmo, SE 205 02, Sweden
    Biochem Biophys Res Commun 292:1092-7. 2002
    ..The ability of CD-31 to signal dynamic alterations in the cytoskeleton, particularly the Ca(2+)-induced actin depolymerization, further explains how neutrophils can squeeze themselves out between adjacent endothelial cells...
  26. ncbi request reprint Engagement of beta2 integrins recruits 14-3-3 proteins to c-Cbl in human neutrophils
    Fredrik Melander
    Experimental Pathology, Department of Laboratory Medicine, Lund University, Malmo University Hospital, Entrance 78, SE 205 02 Malmo, Sweden
    Biochem Biophys Res Commun 317:1000-5. 2004
    ..Consequently, c-Cbl can independently target proteins for degradation or intracellular localization and may initiate an anti-apoptotic signal in neutrophils...